Testosterone Formulations Monitoring Bundle

What Is the Testosterone Formulations Drug Class?

The testosterone formulations drug class comprises all pharmaceutical preparations of the endogenous androgen testosterone, modified by esterification, vehicle selection, or device design to achieve a specific absorption profile. The class sits within the broader androgen category and is governed by Schedule III controlled-substance regulations in the United States [1].

Every agent in the class delivers the same active molecule. Differences in half-life, peak-to-trough ratio, application site, and transfer potential drive formulation selection for individual patients.

Pharmacological Mechanism

Testosterone enters target cells by passive diffusion, binds the intracellular androgen receptor, and the ligand-receptor complex translocates to the nucleus to regulate gene transcription. In androgen-sensitive tissues, 5-alpha-reductase converts testosterone to dihydrotestosterone (DHT), the more potent androgen responsible for prostate growth and scalp follicle effects. Peripheral aromatase converts testosterone to estradiol (E2), which governs bone mineral density, libido, and cardiovascular signaling in men [2].

Diagnostic Threshold for Initiating Therapy

The Endocrine Society's 2018 Clinical Practice Guideline states: "We suggest making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone deficiency and unequivocally and consistently low serum testosterone concentrations." [3] Two separate morning total testosterone measurements below 300 ng/dL, drawn before 10 a.m. On non-consecutive days, are required before prescribing. A single low value is insufficient.

Overview of All Five Formulation Classes

Choosing a formulation is a clinical negotiation between pharmacokinetics, patient lifestyle, partner/child transfer risk, insurance coverage, and adherence probability. No single formulation is universally superior.

Injectable Testosterone Esters

Testosterone cypionate (Depo-Testosterone) and testosterone enanthate (Xyosted, compounded) are the workhorses of TRT in the United States. Both are long-chain esterified androgens in an oil vehicle; depot release after IM or subcutaneous injection produces a peak at 24 to 72 hours and a trough at day 7 to 14 [4].

Typical starting dose: testosterone cypionate 100 mg IM or subcutaneous weekly, or 200 mg every two weeks. Weekly dosing produces a trough-to-peak swing of roughly 300 to 400 ng/dL vs. The 600 to 800 ng/dL swing seen with biweekly dosing. Smaller, more frequent injections reduce symptomatic oscillations.

Testosterone undecanoate (Aveed) is a very-long-acting ester administered 750 mg IM at weeks 0, 4, and then every 10 weeks. Aveed requires an FDA-mandated REMS program due to a rare but serious risk of pulmonary oil microembolism; patients must be observed in a healthcare setting for 30 minutes post-injection [5].

Transdermal Gels and Solutions

Testosterone gel 1% (AndroGel 1%), gel 1.62% (AndroGel 1.62%, Testim 1%), gel 2% (Fortesta), and topical solution 2% (Axiron) deliver testosterone through the skin. Steady-state serum levels are reached within 24 to 72 hours of consistent daily application.

Transfer to female partners and children is the primary safety concern. The FDA's label for AndroGel carries a black-box warning about secondary exposure in children, documented to cause premature puberty and clitoral/penile enlargement [6]. Prescribers must counsel patients to wash hands after application, cover the site with clothing, and avoid skin-to-skin contact until the gel dries.

Nasal Testosterone Gel

Natesto (testosterone nasal gel 4.5 mg per actuation) is the only non-systemic-site nasal androgen. Dosing is 11 mg (one actuation per nostril) three times daily. Its short half-life means peak levels occur within 40 minutes and return to near-baseline within hours, which substantially reduces erythrocytosis risk compared with injectables [7].

Natesto is particularly suitable for men who want to preserve fertility because its intermittent pulsatile delivery suppresses LH/FSH less completely than depot formulations. A 2019 study published in the Journal of Urology (N=90) found that 85.6% of Natesto users maintained sperm concentration above 15 million/mL at 16 weeks vs. 3.2% with testosterone cypionate [8].

Buccal Testosterone

Striant (30 mg testosterone buccal system) is applied to the gum above the incisor twice daily. It releases testosterone through the buccal mucosa. Gum irritation occurs in roughly 16% of users, which limits long-term adherence. Serum levels are steady but modest; many patients find achieving levels above 500 ng/dL difficult without dose escalation [9].

Subcutaneous Pellets

Testopel pellets (75 mg each) are implanted subcutaneously in the gluteal or lateral hip area under local anesthesia. Three to ten pellets per procedure deliver 3 to 6 months of testosterone release. Levels peak at 1 month and taper gradually.

Pellets have no daily-adherence burden, which suits patients with compliance challenges. The main drawbacks: pellet extrusion occurs in 5 to 8% of procedures, minor infection in 1 to 2%, and dose cannot be adjusted once implanted [10].

Pre-Treatment Baseline Evaluation

Before writing any testosterone prescription, a structured baseline evaluation is non-negotiable. The monitoring bundle begins here.

Required Laboratory Panel

| Test | Rationale | |---|---| | Total testosterone (×2, AM, non-consecutive days) | Confirm diagnosis | | LH and FSH | Classify as primary vs. Secondary hypogonadism | | SHBG and calculated free T | Relevant when SHBG is suspected to be high or low | | Hematocrit / CBC | Detect pre-existing erythrocytosis | | PSA (men age ≥40 or any age with prostate symptoms) | Baseline for safety surveillance | | Lipid panel | Testosterone may lower HDL | | Liver function tests | Relevant for oral formulations; baseline for all | | Estradiol (sensitive LC-MS/MS assay) | Baseline for aromatization surveillance |

Contraindications That Must Be Screened Before Prescribing

Do not prescribe testosterone to men with:

• Prostate cancer (any stage) or breast cancer [3]
• Hematocrit >54% at baseline
• Untreated severe obstructive sleep apnea
• Uncontrolled heart failure (NYHA Class III, IV)
• Desire for fertility in the near term (unless using Natesto plus a fertility protocol)

A 2023 meta-analysis in the European Journal of Endocrinology (23 RCTs, N=3,431) found no statistically significant increase in major adverse cardiovascular events (MACE) with testosterone therapy in men without pre-existing cardiovascular disease, but the authors noted that high-quality data in men with recent MI or stroke remain insufficient [11].

The Core Monitoring Bundle: Timelines and Thresholds

A monitoring bundle is only useful if it specifies who orders what, when, and what action each result triggers.

Month 3 Visit: First Post-Initiation Check

Draw labs 3 months after the first dose, or after dose adjustment. For injectables, draw at mid-cycle (e.g., day 4 to 5 of a weekly injection schedule, or day 7 of a biweekly schedule). For gels, draw 2 to 8 hours post-application after at least 2 weeks of consistent use.

Targets at month 3:

• Total testosterone: 400 to 700 ng/dL (mid-cycle for injectables)
• Hematocrit: <54%
• Estradiol: 20 to 40 pg/mL (sensitive assay)
• PSA: no rise >1.4 ng/mL above baseline

If hematocrit exceeds 54%, hold testosterone, investigate secondary causes (sleep apnea, iron deficiency, renal disease), and consider phlebotomy. Resume at a lower dose or longer interval once hematocrit falls below 50% [3].

Month 6 Visit: Stability Confirmation

Repeat CBC, PSA, testosterone, and metabolic panel. Assess symptom response using a validated tool such as the Aging Males' Symptoms (AMS) scale or the International Index of Erectile Function (IIEF).

If the patient is symptomatically improved and labs are within target, transition to every-6-month surveillance.

Annual Monitoring (Ongoing)

Once stable, annual labs include:

• Total testosterone (timing per formulation)
• Hematocrit
• PSA (men age ≥40)
• Fasting lipids
• Estradiol if symptoms of excess (gynecomastia, water retention, mood lability)
• Bone mineral density (DEXA) every 1 to 2 years if baseline osteopenia was present

The Endocrine Society 2018 guideline recommends: "We suggest checking hematocrit at baseline, at 3 to 6 months, and then annually." [3] That interval is a floor, not a ceiling. Men with prior erythrocytosis, sleep apnea, or high-altitude residence may warrant every-3-month CBC indefinitely.

PSA Surveillance Triggers

PSA monitoring follows a tiered response protocol:

1. PSA rise >1.4 ng/mL from baseline within any 12-month period: refer to urology before continuing testosterone.
2. PSA velocity >0.4 ng/mL per year averaged over 2 years: refer to urology.
3. Any single PSA >4.0 ng/mL: refer to urology regardless of rate of rise.
4. Abnormal digital rectal exam at any point: refer to urology.

These thresholds align with the AUA's PSA Early Detection Guideline (2023) [12] and the Endocrine Society's TRT safety recommendations [3].

Hematological Safety: Erythrocytosis Management

Erythrocytosis (hematocrit >54%) is the most common dose-limiting adverse effect of testosterone therapy, occurring in 5 to 25% of treated men depending on the formulation and dose.

Why Injectables Carry Higher Erythrocytosis Risk

High peak testosterone levels after IM or subcutaneous injection stimulate erythropoietin production more intensely than steady-state transdermal or nasal delivery. A retrospective cohort study of 11,173 men (Baillargeon et al., J Clin Endocrinol Metab, 2014) found that injectable testosterone users had a 2.8-fold higher odds of erythrocytosis vs. Transdermal users [13].

Practical Dose Adjustments for Erythrocytosis

• Cypionate/enanthate: reduce dose by 25 to 50 mg per injection or extend interval by 1 week.
• Gels: step down one dose tier (e.g., AndroGel 1.62% from 40.5 mg to 20.25 mg daily).
• Pellets: at next insertion, reduce pellet count by 1 to 2.
• Nasal gel: consider switching from cypionate to Natesto if erythrocytosis is recurrent.

Estradiol Management: Aromatase Inhibitor Use and Misuse

Aromatization of testosterone to estradiol is physiologically necessary in men. Estradiol below 15 pg/mL in men on TRT is associated with bone loss, low libido, and depressive symptoms [14].

When Aromatase Inhibitors Are Appropriate

Anastrozole 0.5 to 1 mg twice weekly or exemestane 12.5 mg every other day may be considered when:

• Estradiol exceeds 50 pg/mL on a sensitive assay, AND
• The patient has symptomatic gynecomastia or significant water retention, AND
• Dose reduction of testosterone has not resolved the problem.

The Endocrine Society guideline explicitly discourages routine aromatase inhibitor co-prescription and states they should be reserved for men with "breast tenderness or gynecomastia" who cannot tolerate dose reduction [3]. Blanket AI co-prescription to keep estradiol "in the 20s" is not evidence-based and risks estradiol-deficiency complications.

Monitoring Estradiol

Use the liquid chromatography-tandem mass spectrometry (LC-MS/MS) estradiol assay, not the standard immunoassay, in men. Immunoassays are calibrated for the estradiol range typical in women and consistently overestimate values in men by 20 to 30% [14].

Fertility Preservation on Testosterone Therapy

All exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis. Within 3 months of initiating therapy, most men develop oligospermia or azoospermia. This is the single most under-counseled aspect of TRT.

Options for Men Who May Want Children

1. Sperm banking before starting testosterone. This costs roughly $400, $1,000 for collection and $200, $500 annually for storage. It is the simplest insurance policy.

2. Natesto plus gonadotropin support. As described above, Natesto's pulsatile profile preserves LH/FSH in many men. Adding hCG 500 IU subcutaneously three times weekly maintains intratesticular testosterone production and spermatogenesis in the majority of patients.

3. Clomiphene citrate or enclomiphene as a testosterone-sparing alternative. These selective estrogen receptor modulators block hypothalamic estrogen receptors, increase GnRH pulsatility, and raise endogenous LH, FSH, and testosterone without axis suppression. Testosterone levels achievable are typically lower (350 to 550 ng/dL) than with exogenous administration.

Recovery of spermatogenesis after stopping testosterone generally takes 6 to 18 months, but recovery is not guaranteed in men who were on therapy for more than 5 years or who had pre-existing subfertility [15].

Formulation-Specific Prescribing Notes

Testosterone Cypionate: Writing the Prescription

A standard starting prescription for weekly self-injection reads: Testosterone cypionate 200 mg/mL, dispense 10 mL vial, inject 0.5 mL (100 mg) subcutaneously every 7 days. Subcutaneous injection using a 27-gauge 0.5-inch needle in the abdominal fat reduces injection-site discomfort and produces a smoother pharmacokinetic curve than traditional IM injection [16].

Testosterone Gels: Counseling Points That Reduce Transfer Risk

• Apply to shoulders, upper arms, or abdomen (product-specific; verify label).
• Allow 5 minutes drying time before covering with clothing.
• Wash hands with soap and water immediately after application.
• Shower before physical contact with partners or children if application was within 6 hours.
• Keep gels away from pets; secondary virilization in female dogs has been reported.

Testosterone Undecanoate (Aveed): REMS Compliance

Aveed is only dispensable through REMS-certified healthcare settings. The 30-minute post-injection observation requirement is not optional. Pulmonary oil microembolism presents as cough, chest pain, or dyspnea within minutes of injection; anaphylaxis has also been reported [5]. Office staff must be trained in recognition and initial management.

Drug Interactions and Complicating Conditions

| Drug / Condition | Interaction | Clinical Action | |---|---|---| | Warfarin | Testosterone potentiates anticoagulant effect | Check INR at 1 and 4 weeks after starting or adjusting dose | | Insulin / oral hypoglycemics | Testosterone improves insulin sensitivity; hypoglycemia risk increases | Monitor fasting glucose; reduce antidiabetic doses cautiously | | Corticosteroids | Additive fluid retention and hematocrit elevation | Monitor BP and hematocrit more frequently | | Obstructive sleep apnea | Testosterone may worsen OSA severity | Ensure CPAP compliance; consider PSG re-evaluation | | CYP3A4 inhibitors (e.g., ketoconazole) | May raise testosterone levels unpredictably | Monitor serum T more frequently |

Switching Between Formulations

Patients sometimes need to switch formulations due to skin reaction, erythrocytosis, lifestyle change, or insurance coverage changes. Follow these principles:

1. Do not overlap full doses of two formulations simultaneously.
2. When transitioning from a long-acting injectable (Aveed) to weekly cypionate, time the first cypionate dose for what would have been the next scheduled injection week.
3. When transitioning from gel to injectable, draw a final gel-level check on the last day of gel use, then begin injectable at week 1.
4. After any formulation switch, repeat labs at 6 to 8 weeks to confirm target range.

Special Populations

Older Men (Age &ge;65)

The Testosterone Trials (TTrials), a coordinated set of seven double-blind RCTs (N=788 men, mean age 72), published in NEJM in 2016, found that testosterone treatment in older men with low levels improved sexual function (mean IIEF score increase of 2.64 points, P<0.001) and bone mineral density but showed no significant benefit for vitality or physical function at 12 months [17]. The cardiovascular substudy showed a greater increase in coronary artery plaque volume in the testosterone group (mean 39 mm³ increase vs. 6 mm³ in placebo), raising unresolved safety questions in older men with subclinical coronary disease.

Prescribe at the lower end of the dose range in men age ≥65. Target serum T of 400 to 500 ng/dL rather than the upper mid-range.

Men With Type 2 Diabetes

Hypogonadism and type 2 diabetes are bidirectionally linked; roughly 40% of men with T2DM have low testosterone. The TRAVERSE trial (N=5,246, published NEJM 2023) randomized men age 45 to 80 with hypogonadism and pre-existing cardiovascular disease or elevated CV risk to testosterone gel 1.62% vs. Placebo. At 33 months median follow-up, the testosterone group showed non-inferior MACE rates (7.0% vs. 7.3% placebo), though atrial fibrillation events were numerically higher in the testosterone arm (3.5% vs. 2.4%, P=0.02) [18].

In men with T2DM on testosterone, monitor HbA1c every 6 months; antidiabetic regimens may require downward adjustment within the first 3 to 6 months of therapy.